VMT treatment launched in Denmark and Sweden

JETREA (ThromboGenics, Leuven, Belgium) has launched in Denmark and Sweden with roll out of the drug to follow shortly in Finland and Norway. These launches will be performed by ThromboGenics partner, Alcon.

Earlier this year, JETREA was approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, by the European Commission and since then it has been launched in the UK and Germany, in Europe.

Dr Patrik de Haes, CEO of ThromboGenics, stated, “We look forward to further launches across the Nordic region and other countries to ensure that patients are able to have access to the first pharmacological treatment for VMT including when associated with macular hole of diameter less than or equal to 400 microns.”

If you would like more information on JETREA and its availability please visit ThromboGenic’s website.